ArticlePediatric surgery international2007
Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients.
Article in Pediatric surgery international, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.Annals of surgery · 2012Trial
- Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee.Pediatric blood & cancer · 2026Article
- Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin.BMC complementary medicine and therapies · 2023Article
- Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases.Cancer management and research · 2022Article
- Review
- Pelvic neuroblastoma presenting with acute urinary retention and acute kidney injury.Urology case reports · 2019Article
- Article
- Article
- Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients.Pediatric surgery international · 2016Article
- Case 3: a toddler with orbital swelling.Pediatric radiology · 2015Article
- Article
- RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.Oncogene · 2014Article
- Epidemiological and clinical characteristics of neuroblastoma in southern iran.Iranian journal of pediatric hematology and oncology · 2014Article
- Primary pediatric cardiac malignancies: the SEER experience.Pediatric surgery international · 2013Article
- A clinical update and radiologic review of pediatric orbital and ocular tumors.Journal of oncology · 2013Article
- Osteosarcoma: improvement in survival limited to high-grade patients only.Journal of cancer research and clinical oncology · 2011Article
- Population-based survival estimates for childhood cancer in Australia during the period 1997-2006.British journal of cancer · 2010Article
- The role of surgery in the treatment of neuroblastoma.Surgery today · 2010Review
- Incidence, ocular manifestations, and survival in children with neuroblastoma: a population-based study.American journal of ophthalmology · 2010Article
- Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database.Clinical orthopaedics and related research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to define current incidence trends and outcomes for pediatric patients with neuroblastoma. The SEER registry was queried from 1973 to 2002. Overall, 1,646 patients with neuroblastoma were identified. The annual incidence has remained unchanged at 0.9 per 100,000. The median age of the population was 1 year, with 42% of patients presenting at <1 year of age. The majority of tumors arose in the retroperitoneum (75.6%) with the remainder located in the mediastinum (15.3%), cervical region (6.6%) and pelvis (2.2%). Markedly improved survival has been noted in each decade (P < 0.002). Sixteen percent of lesions were over 10 cm in greatest dimension, while 84% were high-grade. Disease-specific survival at 1, 2, 5 and 20 years for the entire cohort was 81, 70, 61 and 59%, respectively. Superior survival was observed for infants <1 year of age (P < 0.001). Neuroblastomas in the mediastinum and pelvis had a better prognosis (P < 0.05) while high-grade and lesions over 10 cm carried a worse prognosis (P < 0.022). Surgery but not radiotherapy was associated with improvement in survival (P < 0.001). Multivariate analysis identified age, tumor location, stage, decade of diagnosis and surgical treatment as independent prognostic factors. Neuroblastoma remains a common malignancy with markedly improving patient outcomes. Early diagnosis and surgical therapy continue to provide the best chance for cure. More effective therapies for patients presenting over 1 year of age or those with advanced disease are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.